Skip to contentpdufa.bio

PMN310 PRECISE-AD

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

PMN310 PRECISE-AD is a ProMIS Neurosciences Inc. program in mild cognitive impairment due to AD or mild AD. Its next catalyst is a Readout in Q1 2027.

PMN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Mild cognitive impairment due to AD or mild AD. Sponsor: ProMIS Neurosciences Inc. (PMN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027PMN

Questions

When is PMN310 PRECISE-AD's next FDA decision or readout?

The next tracked catalyst for PMN310 PRECISE-AD is a Readout in Q1 2027.

What happened at PMN310 PRECISE-AD's most recent FDA decision?

No FDA decision for PMN310 PRECISE-AD is in our archive yet.

What is PMN310 PRECISE-AD used for?

In our records PMN310 PRECISE-AD is under review or in development for Mild cognitive impairment due to AD or mild AD.

Who makes PMN310 PRECISE-AD?

ProMIS Neurosciences Inc. (PMN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.